Psoriasis is a chronic inflammatory skin disease and is prevalent in 2-3% of the world population.1 It has several phenotypes of which erythrodermic psoriasis is an uncommon and severe variant.2 It is characterized by erythema involving more than 75% or 90% of the body surface area, according to different authors.2,3 We present a case of erythrodermic psoriasis associated with a recently detected human immunodeficiency virus (HIV) infection.

A 65-year-old male patient with chronic psoriasis since he was 14 years old attended regular checkups and had irregular topical corticosteroid therapy. Over the course of two weeks, erythematous scaly plaques increased both in extension and depth. The patient reported severe skin pain (10/10 on the visual analogue scale), fever up to 39.7°C, and weight loss of approximately 3kg in two weeks. He was not on any new medication.

Physical examination revealed purple-erythematous plaques with fine scaling on the scalp, trunk, and upper and lower extremities, compromising 90% of his body surface area (Figure 1). There were no pustules, and the mucosa was not affected. A complete blood count showed mild leukocytosis (11,590 white blood cells μl; 64% neutrophils, 24% lymphocytes, 4% eosinophils), 87mg/l C-reactive protein (normal range: 0-10mg/l). Liver enzymes, blood chemistry, kidney function, and electrolytes showed no alterations. Blood culture tested positive for Staphylococcus aureus. The patient was admitted to hospital for workup and management. Skin section showed hyperkeratosis with intracorneal pustules, agranulocytosis, regular acanthosis, dermis with dilated blood vessels, and lymphocyte infiltrate, all these findings being consistent with psoriasis (Figure 2).

Figure 1.

Patient with erythrodermic psoriasis and HIV infection of recent diagnosis. Purple-erythematous plaques with fine scaling extend from trunk to upper and lower extremities

(0.64MB).

Figure 2.

Hyperkeratosis and intracorneal pustules, agranulocytosis, regular acanthosis, papillary dermis with dilated blood vessels, and lymphocyte infiltrate Hematoxylin & eosin, X100

(2.86MB).

Because of the severity of his case and the need for subsequent systemic therapy, HIV enzyme immunoassay was performed, testing positive and later confirmed. Plasma HIV viral load and CD4 cell count were performed, showing 117,000 copies/ml and 632 cells/ul, respectively, confirming an acute infection. Systemic antibiotic therapy was administered along with antiretroviral therapy (emtricitabine/tenofovir and raltegravir), associated with acitretin 25mg once a day, with a good response in 8 weeks.

Erythrodermic psoriasis is a rare type of psoriasis, present in 1% to 2.25% of all psoriatic patients,2 and constitutes the main cause of erythroderma, comprising 25% of the cases.2 Erythrodermic psoriasis mostly presents in adult males, although it has been reported in different age groups, including congenital cases.3 Even though erythrodermic psoriasis may be the first manifestation of psoriasis, it usually manifests in patients with longstanding chronic psoriasis, generally 11 to 18 years after diagnosis.3

Reported triggering factors include HIV infection, emotional stress, intense ultraviolet light exposure, use of topical tar products, alcoholism, abrupt withdrawal of oral or topical corticosteroids, and methotrexate therapy. Erythrodermic psoriasis is associated with severe and even fatal complications like sepsis, acute kidney damage, respiratory distress, electrolyte imbalance, severe anemia, altered thermoregulation, protein depletion, and cardiac failure.3 The prevalence of psoriasis is similar in patients with HIV compared to the general population.4 It can appear as the first manifestation of HIV infection and should be suspected in new cases and patients with sudden worsening of previously stable psoriasis. In our case, a high viral load and high CD4 cell count confirmed an acute infection with erythrodermic psoriasis as the first manifestation of HIV infection. Psoriasis can present throughout the course of immunodeficiency, but its severity is proportional to the degree of immunosuppression, being most severe when CD4 count falls below 100 cells per microliter. Even though HIV-associated psoriasis can present with any phenotype, erythrodermic, guttate, and acral psoriasis and psoriatic arthritis tend to appear more frequently than in HIV-negative individuals.4,5

There are no trials or guidelines on the treatment of erythrodermic psoriasis in patients with HIV infection. Treatment of moderate to severe HIV-associated psoriasis poses a therapeutic challenge, since most systemic treatments are immunosuppressive and could lead to severe complications. In 2010 the Psoriasis National Foundation recommended6 antiretroviral therapy as the first line of treatment for HIV-associated psoriasis, which was reported to be effective in a number of cases and clinical trials. Antiretroviral therapy includes nucleoside and non-nucleoside reverse transcriptase inhibitors, protease inhibitors, and fusion inhibitors and has demonstrated improvement in HIV-associated psoriasis. Phototherapy with either ultraviolet B radiation or psoralen and ultraviolet A is another first-line treatment recommended for patients with moderate to severe HIV-associated psoriasis without erythroderma.6 However, one must balance the benefits of ultraviolet A exposure against the potential risk of skin cancer, the potential rise in HIV recount, and the risks secondary to the use of photosensitizing drugs. Oral retinoids are an effective alternative that do not cause immunosuppression,1,7 and may be given together with psoralen and ultraviolet A radiation.

Cyclosporine, methotrexate, and biological drugs (anti-tumor necrosis factor and anti-interleukins 12 to 23) are reserved for refractory cases.6,8 Because in vitro studies show that TNF stimulates HIV intracellular transcription, biological therapy targeting TNF could be effective, although this benefit should be balanced against the augmented risk of opportunistic infections and the fact that TNF is involved in granuloma formation. There is scarce experience using etanercept, infliximab, adalimumab, and ustekinumab.8-10 Indication for the use of the first-line biological agents is unclear, and they may be considered an effective choice for patients with stable HIV infection who are adherent to medication and have failed to respond to other psoriasis treatment modalities.8,9

Financial support: None.

Conflict of interest: None.